Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE
Authors:
- Irina VelikyanIVIrina Velikyan
- Hui XuHXHui Xu
- Manoj NairMNManoj Nair
- Håkan HallHHHåkan Hall
- 1 July 2012
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 39 (5) , 628-639
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide massNuclear Medicine and Biology, 2010
- Progress and challenges in neuroendocrine and neural crest tumours: molecular imaging and therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Pharmacotherapy of neuroendocrine cancersExpert Opinion on Pharmacotherapy, 2008
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?European Journal of Nuclear Medicine and Molecular Imaging, 2007
- Radiolabeled Peptides in Nuclear Oncology: Influence of Peptide Structure and Labeling Strategy on Pharmacology2004
- Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic useEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- Development of selective antibodies against the human somatostatin receptor subtypes sst1–sst5Molecular Brain Research, 1997
- Somatostatin Binding Sites in Human and Monkey Brain: Localization and CharacterizationJournal of Neurochemistry, 1986